A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Overview of attention for article published in Journal of Hematology & Oncology, January 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

blogs: 1 blog

Citations

dimensions_citation: 56 Dimensions

Readers on

mendeley: 43 Mendeley

Summary Blogs Dimensions citations

So far, Altmetric has seen 1 blog post.

Selinexor

New Drug Approvals, 16 Jul 2019

Selinexor セリネクソル KPT-330 UNII-31TZ62FO8F (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N‘-pyrazin-2-ylprop-2-eneh…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.